Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2012

View Archived Issues

Ablynx and Merck Serono advance ALX-0751 into preclinical development

Benefits seen with rhLAMAN in patients with alpha-mannosidosis

Mundipharma launches Flutiform in Germany

CHMP recommends VEGF Trap-Eye in wet AMD

CHMP gives positive opinion on Cialis in new indication

Kyorin files NDA in Japan for asthma drug

Chinese group synthesizes new SGLT2 inhibitors

Roche describes new dual dopamine/serotonin receptor ligands

Novel gamma-secretase modulators disclosed by Roche

ProteoTech presents novel agents for Parkinson's disease

Researchers at Repligen divulge new HDAC inhibitors

Zalicus presents new agents for pain

Herb-based lotion relieves symptoms of atopic dermatitis

Melatonin identified as a marker of brain serotonin metabolism

First patient enrolled in Isofol Medical's phase I/II Modufolin trial

Northwest Biotherapeutics prepares for phase I/II DCVax-Direct study

Galderma and NovaBay enroll first patients in phase IIb NVC-422 trial

Novartis researchers identify novel orexin receptor antagonists for sleep disorders

Researchers evaluate CPP-109 in Tourette's syndrome

Valeant Pharmaceuticals acquires Visudyne from QLT

Novartis reports results from phase III RELAX-AHF study

Novel PLK1 inhibitors show potent antiproliferative activity in vitro

Novartis obtains positive CHMP opinions for Galvus and Eucreas

Daiichi Sankyo completes phase III study of prasugrel in ACS

Avastin recommended for approval of recurrent, platinum-sensitive ovarian cancer in Europe

EMA committee recommends approval of enzyme-based debriding agent for burn care

Janssen Pharma seeks approval in Japan for paliperidone extended-release injection

Votubia recommended for approval in Europe